CAR-GPRC5D is under clinical development by Nanjing IASO Biotherapeutics and currently in Phase I for Relapsed Multiple Myeloma. According to GlobalData, Phase I drugs for Relapsed Multiple Myeloma have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CAR-GPRC5D’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CAR-GPRC5D overview

Gene-modified cell therapy is under development for the treatment of relapsed or refractory multiple myeloma or plasma cell leukemia. The therapeutic candidate comprises of autologous T cells genetically engineered through lentiviral vector to express chimeric antigen receptors (CAR) targeting G protein coupled receptor family C group 5 member D (GPRC5D).

Nanjing IASO Biotherapeutics overview

Nanjing IASO Biotherapeutics (IASO Biotherapeutics) is a biopharmaceutical company that develops and manufactures tumor cell immunotherapy and antibody drugs. IASO Biotherapeutics is headquartered in Nanjing, Jiangsu, China.

For a complete picture of CAR-GPRC5D’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.